FMP
VolitionRx Limited
VNRX
AMEX
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company operates Nucleosomics a technology platform for blood test. VolitionRx Limited is based in Austin, Texas.
0.481 USD
-0.0254 (-5.29%)
Historical Prices
From:
To:
About
ceo
Mr. Cameron Reynolds MBA
sector
Healthcare
industry
Medical - Diagnostics & Research
website
https://www.volition.comexchange
AMEX
Description
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company operates Nucleosomics a technology platform for blood test. VolitionRx Limited is based in Austin, Texas.
CIK
0000093314
ISIN
US9286611077
CUSIP
928661107
Address
13215 Bee Cave Parkway
Phone
646 650 1351
Country
US
Employee
85
IPO Date
Mar 2, 2012
Financial Statement
Earnings
VNRX Financial Summary
CIK
0000093314
Exchange
AMEX
Industry
Medical - Diagnostic...
Sector
Healthcare
CUSIP
928661107
ISIN
US9286611077
Country
US
Price
0.48
Beta
1.16
Volume Avg.
173.99k
Market Cap
48.42M
Shares
-
52-Week
0.42-0.91
DCF
-0.37
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-1.55
P/B
-
Website
https://www.volition.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest VNRX News
Rayan Ahmad
Mar 31, 2025
VolitionRx Limited's Financial Performance Analysis
VolitionRx Limited, trading as NYSEAMERICAN:VNRX, is a company focused on developing blood tests for cancer detection. On March 31, 2025, VNRX reported an earnings per share (EPS) of -$0.06, aligning with the estimated EPS of -$0.06. The company generated a revenue of approximately $593,000, surpassing the estimated revenue of about $545,000. Despite matching EPS estimates, VNRX's financial metrics reveal challenges. The company has a negative price-to-earnings (P/E) ratio of -1.62, indicating ...
Alex Lavoie
Mar 28, 2025
VolitionRx Limited's Upcoming Earnings Report: A Deep Dive i...
VolitionRx Limited, trading as NYSEAMERICAN:VNRX, is a company focused on developing blood tests for cancer detection. As a player in the biotechnology sector, it faces competition from other firms in the diagnostic and cancer detection space. On March 31, 2025, VNRX will release its quarterly earnings, with Wall Street estimating an earnings per share of -$0.06 and revenue of $545,340. The company has scheduled a conference call on the same day at 4:30 p.m. U.S. Eastern Time to discuss its fin...
Rayan Ahmad
Mar 21, 2025
VolitionRx Limited's Upcoming Earnings and Innovations in Ca...
VolitionRx Limited (NYSE American: VNRX) is a multi-national epigenetics company known for its innovative cancer diagnostics. The company is set to release its quarterly earnings on March 24, 2025, with analysts predicting an EPS loss of $0.06 and revenue of approximately $545,340. The earnings report will be released before the market opens. VolitionRx is making strides in the cancer diagnostics field with its Nu.Q® Cancer diagnostics test. This test can detect 21 types of human cancers with h...
PRNewsWire
Aug 6, 2024
VolitionRx Limited Schedules Second Quarter 2024 Earnings Co...
Conference call to take place on Thursday August 15 at 8:30 a.m. U.S Eastern Time HENDERSON, Nev.
InvestorPlace
Jan 18, 2024
Next Big Thing: 3 Biotech Stocks to Watch for Groundbreakin...
The International Monetary Fund believes that most of the impact from tighter money policies has already affected the U.S. economy, with the rest expected this year. Despite worries about a recession, the U.S. has shown resilience and strong growth since interest rates started going up in March 2022.
Proactive Investors
Jan 4, 2024
VolitionRx has 'compelling plans' to advance veterinary care...
VolitionRx (NYSE-A:VNRX) has outlined its plans to advance its veterinary diagnostics platform after a successful 2023. Among the notable achievements in the past year, Volition successfully launched the Nu.Q Vet Cancer Test in significant markets through various licensing, supply, and distribution agreements.
Proactive Investors
Dec 5, 2023
Volition secures €5M in financing from Belgium's Wallonie En...
VolitionRx (NYSE-A:VNRX) told investors it has secured €5 million (roughly $5.5 million) in financing from Belgium's Wallonie Entreprendre (WE) for the ongoing development of its Nu.Q product portfolio. The multi-national epigenetics company said the funds will also be used to advance the clinical and regulatory program for Nu.Q NETs, which it believes will aid the early diagnosis of diseases such as sepsis, as it works with leading clinicians and researchers to help facilitate the effective int...
Seeking Alpha
Nov 15, 2023
VolitionRx Limited (VNRX) Q3 2023 Earnings Call Transcript
VolitionRx Limited (NYSE:VNRX ) Q3 2023 Earnings Conference Call November 15, 2023 8:30 AM ET Company Participants Scott Powell - Executive Vice President, Investor Relations Cameron Reynolds - President and Group Chief Executive Officer Terig Hughes - Group Chief Financial Officer Tom Butera - Chief Executive Officer, Volition Veterinary Subsidiary Andrew Retter - Medical Consultant, Volition Louise Batchelor - Chief Marketing and Communications Officer Conference Call Participants Ross Osborn ...
